Ensysce Biosciences, Inc.

Nasdaq:ENSCOTC:ENSCW

Pharmaceutical Preparations·LA JOLLA, CA

Summary Financials

Revenue

$2.2M

-11.6% YoY

FY 2024

Adj. EBITDA

-$10.7M

-480.5% margin

FY 2024

Net Income

$365,954

16.4% margin

FY 2020

EPS (Diluted)

-$70.40

FY 2024

Stock Price

$0.54

-1.3%

2026-03-09

52W Range

$0.31 – $4.93

P/E Ratio

-0.0x

Market Cap

$1.9M

Cash

$1.1M

FY 2024

Total Debt

$994,845

FY 2023

Net Cash

$128,759

FY 2023

Enterprise Value

$1.8M

Debt / EBITDA

0.0x

FY 2024

EV / EBITDA

-0.2x

Employees

—

Revenue

$2.2M

-11.6% YoY

FY 2024

Adj. EBITDA

-$10.7M

-480.5% margin

FY 2024

Net Income

$365,954

16.4% margin

FY 2020

EPS (Diluted)

-$70.40

FY 2024

Stock Price

$0.54

-1.3%

2026-03-09

52W Range

$0.31 – $4.93

P/E Ratio

-0.0x

Market Cap

$1.9M

Cash

$1.1M

FY 2024

Total Debt

$994,845

FY 2023

Net Cash

$128,759

FY 2023

Enterprise Value

$1.8M

Debt / EBITDA

0.0x

FY 2024

EV / EBITDA

-0.2x

Employees

—